Mercury Laboratories Ltd

Mercury Laboratories Ltd has announced the appointment of Mr. Jaydeepsinh Raj as Manager-HR, effective September 03, 2026. This appointment elevates the HR Manager role to senior management. Mr. Raj, aged 35, holds a Bachelor’s Degree in Social Work and brings over 8 years of experience in Human Resource Management, with prior associations at IDMC Limited and Sudeep Pharma Private Limited. The company has provided the necessary disclosures as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mercury Laboratories Ltd has announced its 45th Annual General Meeting (AGM) to be held on September 28, 2026, at 11:30 am IST via Video Conferencing. The company has also submitted its 45th Integrated Annual Report for the financial year ended March 31, 2026. The report highlights key financial figures including Revenue from Operations of ₹7,593.67 Lakhs and Net Profit After Tax of ₹483.40 Lakhs. The e-voting period will commence on September 24, 2026, and conclude on September 27, 2026. The register of members and share transfer books will be closed from September 22, 2026, to September 28, 2026, for the purpose of the AGM and final dividend.

Mercury Laboratories Ltd has issued the notice for its 45th Annual General Meeting (AGM) scheduled for September 28, 2026, at 11:30 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of the audited financial statements for FY 2025-26, declaration of a final dividend of ₹3.50 per equity share, re-appointment of Mr. Dilip R Shah as a director, and approval for payment of remuneration to Ms. Janki R Shah. The Annual Report and AGM Notice are available on the company's website and will be emailed to registered members.

Mercury Laboratories Ltd has announced a change in its senior management for the Injectable Production department. Mr. Sunil Sharma has been appointed as the new Head of Department (HOD) for Injectable Production, effective August 21, 2026. Concurrently, Ms. Seema Salvi has resigned from her position as HOD Injectable Production and Senior Management Personnel (SMP) to pursue better career opportunities. Mr. Sharma brings over 19 years of experience in Injection Production, having previously worked with prominent pharmaceutical companies. The company has provided detailed profiles and reasons for the changes as per SEBI regulations.

Mercury Laboratories Ltd announced that its Board of Directors, at a meeting held on July 25, 2026, approved the unaudited financial results for the quarter ended June 30, 2026. The company also submitted the Limited Review Report from its statutory auditors. The meeting commenced at 9:30 a.m. IST and concluded at 11:33 a.m. IST. The results were prepared in accordance with Indian Accounting Standards and SEBI (LODR) Regulations, 2015. The company operates in a single segment: Pharmaceuticals Products.

Mercury Laboratories Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on July 25, 2026. The company also provided the Limited Review Report from its statutory auditors. The financial results are prepared in accordance with Indian Accounting Standards and SEBI (LODR) Regulations, 2015. The company operates in a single segment, "Pharmaceuticals Products".

Mercury Laboratories Ltd has announced that its Board of Directors will convene on July 25, 2026. The primary agenda item for this meeting is to consider and approve the company's unaudited financial results for the quarter ending June 30, 2026. In line with the company's insider trading policy, the trading window has been closed from July 1, 2026, and will reopen 48 hours after the financial results are declared.

Mercury Laboratories Ltd has announced the closure of its trading window for designated persons and their relatives. This closure is in accordance with SEBI regulations and the company's internal code of conduct. The trading window will be shut effective July 1, 2026, and will reopen 48 hours after the announcement of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to consider these results will be communicated separately.

Mercury Laboratories Ltd has announced the appointment of Mr. Binaya Kumar Panigrahi as the new Plant Head for its Jarod Unit. The appointment is effective from June 11, 2026. Mr. Panigrahi, aged 52, holds a Bachelor's degree in Pharmacy and brings over 24 years of experience in Tablet Manufacturing, having previously worked with Coral Laboratories Limited and Biocon Biological India Limited. This appointment is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mercury Laboratories Ltd has issued a corrigendum to its audited financial results for the quarter and year ended March 31, 2026, due to a typographical error in the balance sheet under current liabilities and an omission in cash flow from financing activities. The corrected financial results, along with the auditor's report, have been resubmitted. The board had earlier recommended a final dividend of 35% i.e ₹3.50 per share for FY26, subject to shareholder approval.